See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: June 1, 2006

Malignant Melanoma Schizophrenia and Schizoaffective Disorders Hip Replacement

(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:

Malignant Melanoma

This is a trial of an investigational drug to treat malignant melanoma that cannot be remedied by surgery. Candidates may include people 18 or older who have recovered from prior therapy, have not been exposed to chemotherapy or radiotherapy within the prior four weeks, and whose cancer has not spread to the brain, liver, or bone. Participants also cannot be pregnant or lactating, or have had recent surgery, a serious infection, or treatment with antiviral drugs.

The research sites are in Minnesota, Missouri, and Texas.

More information

Please see


Schizophrenia and Schizoaffective Disorders

This study will evaluate an investigational medication for schizophrenia. Volunteers 18-55 with schizophrenia or schizoaffective (depressed type) disorders who have primarily negative symptoms and are on risperidone may be eligible. The study will last approximately four months and include 11 outpatient visits.

The research site is in Glendale, Calif.

More information

Please see


Hip Replacement

This study will assess the safety and effectiveness of a 10 mg dose of BAY 59-7939, taken once daily, to prevent blood clots after hip surgery. Volunteers at least 18 who are scheduled for elective total hip replacement but not total bilateral hip replacement may qualify. Additional criteria apply.

The research sites are in Colorado and Florida.

More information

Please see


Copyright 2006 CenterWatch. All rights reserved.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.